Ruxolitinib Associated With Improved Outcomes in Glucocorticoid-Refractory Acute Graft-Versus-Host Disease
The multicenter, randomized REACH2 trial demonstrated that ruxolitinib is efficacious and safe for patients with aGVHD after allogeneic stem cell transplantation.